Pharmacoeconomics

Papers
(The H4-Index of Pharmacoeconomics is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?205
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”93
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling84
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis60
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment54
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment52
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment42
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting39
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy38
Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)38
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment36
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children33
Advancing Methods to Measure and Reward Healthcare Innovation31
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy28
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation28
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned28
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling28
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)28
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review28
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS27
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based 26
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions25
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies24
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment24
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know24
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review24
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review24
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA24
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States24
0.59903287887573